---
schema_version: "secwatch.filing_event.v1"
accession: "0001562762-24-000179"
form_type: "8-K"
ticker: "CHE"
cik: "0000019584"
company_name: "CHEMED CORP"
filed_at: "2024-07-24T23:59:59+00:00"
generated_at: "2026-05-31T17:19:53.039033+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Chemed Q2 adjusted EPS $5.47 (+34.1% YoY); raises FY2024 guidance to $23.55-$23.80

## Summary
- Revenue $595.9M (+7.6%); GAAP EPS $4.65 (+32.5%); adjusted EPS $5.47 (+34.1%).
- VITAS net patient revenue +16.7% to $374.6M; ADC +14.4% to 21,036; adjusted EBITDA +77% to $67.0M.
- Roto-Rooter revenue -5% to $221.3M; adjusted EBITDA -9.2% to $59.8M; margin 27.0%.
- FY2024 adjusted EPS guidance raised to $23.55-$23.80 (from $23.30-$23.70); VITAS EBITDA margin 19.3%-19.7%.
- Repurchased 100k shares for $55.8M; cash $222.9M, no debt; $225.9M remaining buyback authorization.

## SEC filing metadata
- accession: 0001562762-24-000179
- form_type: 8-K
- ticker: CHE
- cik: 0000019584
- company_name: CHEMED CORP
- filed_at: 2024-07-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/19584/000156276224000179/0001562762-24-000179-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/19584/000156276224000179/che-20240724x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001562762-24-000179
- JSON: https://secwatch.observer/filing/0001562762-24-000179.json
- Plain text: https://secwatch.observer/filing/0001562762-24-000179.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.